Phase II Study in Patients With Operable Breast Cancer

Status unconfirmed · Phase 2

Conditions studied: Breast Cancer

In brief

The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.

Key facts

Study ID
NCT00518583
Run by
Aptium Oncology Research Network
People needed
30
Starts
2006-10-01
Expected to finish
2009-09-01
Last updated by the study team
2010-01-15

Who can join

Age: 21 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.